Skip to main content
. 2018 Jun;93(6):645–656. doi: 10.1124/mol.118.111872

Fig. 1.

Fig. 1.

(A–C) Effects of xanomeline (1, 3, 10, and 30 mg/kg) (A), GSK1034702 (0.3, 1, 3, 10, and 30 mg/kg) (B), and TBPB (1, 3, 10, and 30 mg/kg) (C) on scopolamine (1.5 mg/kg)–induced impairments in contextual fear conditioning (inset chemical structures of compounds). Data are expressed as the means ± S.E.M. of eight or more mice per group. Data were analyzed using a one-way analysis of variance with the Tukey multiple comparison test. *P < 0.05; ** P < 0.01; ***P < 0.001 vs. vehicle alone; #P < 0.05 vs. 1.5 mg/kg scopolamine. (D–F) Unbound concentrations (Log M) of xanomeline (D), GSK1034702 (E), and TBPB (F) measured in plasma or brain samples 30 minutes after intraperitoneal injection with increasing concentrations of respective compound. Data are expressed as the means ± S.E.M. of three mice per concentration.